Furthermore, Health Canada has advised that an inspection for the issue of an Establishment License has been scheduled over a number of days commencing 29 November 2010, following which a full Establishment License is expected to issue that will then allow Stirling Pharma to manufacture pharmaceutical drugs.
Stirling Pharma’s 46,000 sqft Cape Breton high-tech GMP pharmaceutical plant includes laboratories for formulation development and includes specialist sections having various capabilities such as high shear mixing, container blending and equipment for the manufacture of modified drug release product.
Stirling Pharma claimed that the facility provides formulation development and testing services, as well as provision for the manufacture and packaging of products in solid and liquid dosage forms.